Valbiotis SA (ALVAL.PA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Sebastien Peltier HDR, Ph.D. | Co-Founder, Chairman of the Management Board & CEO | 242k | -- | 1978 |
| Mr. Stanislas Sordet | CFO & Member of Management Board | 262.32k | -- | -- |
| Mr. Sebastien Bessy | COO & Member of the Management Board | 302k | -- | -- |
| Mr. Pascal Sirvent Ph.D. | CSO & Member of the Management Board | 201k | -- | -- |
| Ms. Murielle Cazaubiel | CMO & Member of the Management Board | 247k | -- | -- |
| Ms. Charlotte Jezequel | Director of HR & Member of Management Board | -- | -- | -- |
| Dr. Josep Infesta | Head of Global Business Development | -- | -- | -- |
Valbiotis SA
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 44
Description
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. The company has a partnership with Leiden University, Vanderbilt University, INAF, CarMeN Laboratory, LAPEC, MEDiS Unit, M2iSH, Clermont-Ferrand Clinical Investigation Center, ADECAL, and IFREMER. Valbiotis SA was incorporated in 2014 and is based in Périgny, France.
Corporate Governance
Upcoming Events
March 3, 2025 at 10:59 AM UTC
Valbiotis SA Earnings Date
Recent Events
Recent Events Information Not Available